ClinicalTrials.gg
RecruitingNCT05959252BLUSHUpdated May 8, 2026

BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

A Phase 2 interventional study of Unfractionated heparin and Bivalirudin in Extracorporeal Membrane Oxygenation Complication, sponsored by Sydney Local Health District. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sydney Local Health District · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this open label randomised clinical trial is to compare Bivalirudin versus Heparin for anticoagulation in patients requiring extracorporeal membrane oxygenation support.

The main question it aims to answer are include the ability to maintain anticoagulation within defined therapeutic range, bleeding and thrombotic complications and a comparison of the total cost of anticoagulation care.

Participants will be randomised to either anticoagulation with Bivalirudin or anticoagulation with Unfractionated Heparin.

Read the detailed description

Rationale:

Anticoagulation whilst on extracorporeal membrane oxygenation (ECMO) is required. Bleeding and thrombotic complications whilst on ECMO are common and may effect the patient outcome. The optimal anticoagulant for ECMO patients is not clear and there exists no randomised control trial data comparing anticoagulants on ECMO. This Phase 2b trial will provide data to enable larger definitive phase III trials to determine the best anticoagulant whilst on ECMO.

Hypothesis: Hypothesis: In adults ECMO patients'; anticoagulation with Bivalirudin results in more samples within therapeutic range than unfractionated Heparin. Total anticoagulation costs with Bivalirudin are similar to unfractionated Heparin.

The objectives of this study is to assess anticoagulation protocol of bivalirudin versus unfractionated heparin and assess the to the cost of each protocol.

02

Conditions studied

  • Extracorporeal Membrane Oxygenation Complication

Keywords

  • ECMO
  • Bivalirudin
  • Heparin
  • Extracorporeal membrane oxygenation
03

In context

Lead sponsor

Sydney Local Health District is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving ECMO
  • Age: 18 years or older
  • Ability to randomise the patient within 4 hours of ECMO support initiation

Exclusion criteria

EXCLUSION CRITERIA

  • Post-cardiotomy ECMO patients
  • to heparin or bivalirudin at time of randomisation e.g., active bleeding
  • Heparin induced thrombotic thrombocytopenia syndrome
  • Where the patient is expected to be disconnected from ECMO in the next day after cannulation.
  • Limitations of care put in place either through patient wishes or the treating medical teams
  • Other reason where the treating physician deems the study is not in the patient's best interest
  • Patients who are suspected or confirmed to be pregnant
  • Inherited bleeding or thrombotic disorders, Systemic Lupus Erythematosus patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Bivalirudin

    Bivalirudin protocol with target activated thromboplastin time (aPTT) of 50-70 seconds

    Drug: Bivalirudin

  • Active comparator
    Unfractionated Heparin

    Unfractionated heparin protocol with target anti-Xa of 0.3-0.5 IU/mL

    Drug: Unfractionated heparin

Interventions

  • DrugHeparinStudies of HeparinHeparin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL

    Also known as: Heparin

  • Bivalirudin protocol with target aPTT 50-70 seconds

06

What researchers measure

Primary outcomes

  1. Time in therapeutic range

    Proportion of monitoring samples within therapeutic range

    Time frame: 30 days

Secondary outcomes

  1. Enrolment rate

    Enrolment rate

    Time frame: 30 days

  2. Reasons for non-enrolment

    Reasons for non-enrolment of eligible patients into the study

    Time frame: 30 days

  3. Crossover between arms

    The number of cross over patients between arms of the study

    Time frame: 30 days

  4. Circuit changes

    The number of circuit changes and length of circuit life

    Time frame: 30 days

  5. Daily mean aPTT and anti-Xa

    Daily mean aPTT and anti-Xa versus stated range

    Time frame: 30 days

  6. Serious adverse events (SAEs)

    Number of SAEs

    Time frame: 30 days

  7. Protocol violations

    Number of protocol violations

    Time frame: 30 days

  8. Thrombotic events

    Number of deep vein thrombosis identified by ultrasound or CT

    Time frame: 30 days

  9. Major bleeding events defined by International Society of Thrombosis and Haemostasis (ISTH)

    Major bleeding was defined according to the criteria as clinically overt bleeding which was fatal or associated with any of the following: (a) a fall in hemoglobin level of 2 g/dL or more or documented transfusion of at least 2 units of packed red blood cells, (b) involvement of a critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular with compartment syndrome, retroperitoneal)

    Time frame: 30 days

  10. Bleeding events defined by Bleeding Academic Research Consortium (BARC)

    Number of bleeding events as per BARC Hemorrhagic complications assessed and adapted as per Bleeding Academic Research Consortium (BARC) Type 0: No bleeding Type 1: Bleeding requiring transfusion of packed red blood cells (PRBC) or reduction of unfractionated heparin Type 2: Bleeding requiring transfusion of PRBC and reduction of unfractionated heparin Type 3: Life-threatening bleeding requiring, transfusion of PRBC, surgical intervention or discontinuation of ECMO Type 4: Any fatal bleeding

    Time frame: 30 days

  11. Survival to Intensive care Unit (ICU) discharge

    Survival to discharge from ICU (percentage of patients surviving to ICU discharge)

    Time frame: 30 days

  12. Survival to hospital discharge

    Hospital Survival (percentage of patients surviving hospital discharge)

    Time frame: 30 days

  13. Blood product usage

    Total amount of red blood cells (RBC), platelets, plasma and blood products used during extracorporeal membrane oxygenation support

    Time frame: 30 days

  14. Cost

    Total cost of of extracorporeal membrane oxygenation support that includes blood products, blood tests and complications (measured in United States dollars)

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
    Recruiting
    • Timothy J Southwood · Contacttimothy.southwood@health.nsw.gov.au · +61295156111
    • Mark Dennis, PhD · Contactmark.dennis@sydney.edu.au · +61295156111
    • Timothy J Southwood · Principal investigator
    • Elliot Worku · Sub investigator
    • Paul Forrest · Sub investigator
    • Richard Totaro · Sub investigator
    • Lucy Wells · Sub investigator
    • Mark Dennis · Sub investigator
    • Ru Carey · Sub investigator
    • Bruce Cartwright · Sub investigator
    • Brian Plunkett · Sub investigator
    • Lianne Khoo · Sub investigator
    • Anthony Keech · Sub investigator
    • Ian Marschner · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jun 2026, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2023
First posted
Jul 25, 2023
StartActual
May 1, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Sep 1, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05959252
Lead sponsor
Sydney Local Health District
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
May 1, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Heparin · Bivalirudin

Start the discussion